That's a great question, and it's one many people with refractory DLBCL are asking. While specific member experiences with these two drugs together aren't available here, what can be shared is some helpful background on both treatments.
Both Zynlonta (loncastuximab tesirine-lpyl) and Glofitamab (Columvi) are approved for Show Full Answer
That's a great question, and it's one many people with refractory DLBCL are asking. While specific member experiences with these two drugs together aren't available here, what can be shared is some helpful background on both treatments.
Both Zynlonta (loncastuximab tesirine-lpyl) and Glofitamab (Columvi) are approved for relapsed or refractory DLBCL, typically after other treatments haven't worked. Glofitamab is a bispecific antibody, meaning it works by:
- Binding to cancer cells on one end
- Attacking and destroying those cancer cells on the other end
Zynlonta is an antibody-drug conjugate that targets and delivers a toxic payload directly to lymphoma cells.
Both are considered later-line options, so your oncologist would be the best person to discuss expected side effects, response rates, and whether this combination makes sense for your specific situation. For real-world experiences from people who've actually been on these treatments, the MyLymphomaTeam community is a wonderful place to post this question — members there have firsthand experience with these newer therapies and are often very open about sharing what they went through. You may find someone who's been on one or both of these drugs and can speak to side effects and outcomes personally. 💙
August 6
Join
Your Privacy Choices
